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Objective. This study was intended to evaluate the eﬃcacy and safety of ligustrazine injection for chronic pulmonary heart
disease (CPHD). Method. Randomized controlled trials (RCTs) of clinical therapeutic studies on CPHD when using ligustrazine
injection were included. Searches were applied to the following electronic databases: the PubMed, the Cochrane Library, EMBASE,
CBM, and AMED. No language restriction was used. All trials included were analyzed according to the criteria of the Cochrane
Handbook. Review Manager 5.0 software was used for data analysis. Result. 34 RCTs with low methodological quality were
included. Compared to conventional medicine treatment alone, ligustrazine injection plus conventional medicine treatment
showed improvement in New York Heart Association classiﬁcation of clinical status (Odds ratio 0.22; 95% CI 0.17 to 0.28)
and depression of pulmonary artery hypertension (weighted mean diﬀerence −4.77; 95% CI −5.85 to −3.68). Three studies had
reported adverse events. No serious adverse eﬀects were reported. Conclusion. While there is some evidence that suggests potential
eﬀectiveness of ligustrazine injection for CPHD, the results were limited by the methodological ﬂaws of the studies. High quality
studies are needed to provide clear evidence for the future use of ligustrazine injection.
1.Introduction
Chronic pulmonary heart disease (CPHD) is a rising major
public health problem worldwide [1]. In China, many tra-
ditional Chinese patent medicines (TCPMs) are regularly
used in CPHD patients in hospital. Few studies reporting
the eﬀectiveness and safety of many commonly used TCPMs
for cor pulmonale have been published in English. Sichuan
lovage rhizome is one kind of traditional Chinese herbal
medicines, which has the function of promoting blood cir-
culation and qi ﬂowing, dispelling pathogenic wind and re-
lieving pain. It has long been used for the treatment of heart
disease and cerebral disease in China. Ligustrazine is an iso-
lated alkali extracted from Sichuan lovage rhizome. It is the
formula is 2,3,5,6-tetramethyl pyrazine. It has eﬀect of dilat-
ing blood vessels, inhibiting platelet aggregation and pre-
ventingthrombopoiesis. Therearetwocommontypes:ligus-
trazine phosphate and ligustrazine hydrochloride. Several
clinical trials have shown that ligustrazine injection might
have the therapeutic eﬀect of improving cardiac function in
patients with CPHD. However, the quality of these trials has
not been assessed systematically. Furthermore, the sponta-
neous evolution of CPHD is diﬃcult to predict. A systematic
paper will be beneﬁcial for current practice and directive for
continuing research for new treatment regimens. The objec-
tive of this review was to assess both positive and negative
eﬀects of ligustrazine injection plus conventional medicine
treatment versus conventional medicine treatment in all
types of CPHD in adults.
2.MaterialsandMethods
2.1. Eligibility Criteria. The eligibility criteria for con-
ducting the survey included administration of ligustrazine
hydrochloride injection for the treatment of CPHD and
duration of treatment and also included trials involving pa-
tients of any age, sex, or CPHD stage. However, we excluded2 Evidence-Based Complementary and Alternative Medicine
pharmacokinetic studies, nonrandomized evaluations, and
animal/laboratory studies.
2.2. Search Strategy. T w or e v i e w e r s( L .S .Y .a n dW .Z .
W.) identiﬁed relevant randomised controlled trials inde-
pendently, including all languages, by a systematic search
of PubMed (1990–2010), Chinese Biomedical Database
(CDROM, 1990–2010), EMBASE (1990 to December 2010),
AMED (1990 to December 2010), Chinese BioMedical Lit-
erature Database (CBM, 1990 to December 2010), the Co-
chrane Library (Issue 2, 2010), and BIOSIS (1997 to
2008). With the following terms: (cor pulmonale or chronic
pulmonary heart disease) AND (Ligustrazine hydrochloride
injection or ligustrazine hydrochloride injection). We used
the wild card term “∗” to enhance the sensitivity of our
search strategy. Reviewers scanned the bibliographies of all
retrieved trials and other relevant publications, including
reviews and meta-analyses, to ensure a thorough search.
2.3.StudySelectionandDataExtraction. Two reviewers (L. S.
Y. and L. Y.) extracted data and evaluated data’s quality and
content independently. We conducted data extraction using
astandardizedprocedure.Initially,abstractswerescreenedto
exclude obviously ineligible reports, and then all remaining
articles were reviewed. We classiﬁed trials and abstracts ac-
cording to drug, patient characteristics, study design, and
therapy duration. Reviewing study design included the fol-
lowing criteria: methods of sequence generation, allocation
concealment, complete description of those who were blind-
ed [2], and use of intention-to-treat analysis and whether the
trial was stopped prior to the planned duration, all method-
ologicalfeaturesin addition capableofimpacting eﬀectsizes.
The primary outcome measures included (1) New York
Heart Association classiﬁcation (NYHA) of clinical sta-
tus; (2) adverse events. The secondary outcome measures
included (1) death, (2) hemodynamics, (3) quality of life as
measured by various instruments.
The data was entered into an electronic database by the
two reviewers separately, avoiding duplicate entries; in the
case where the two entries did not match, an inspection will
be conducted, and a third person may be involved for ver-
iﬁcation. In order to obtain full information regarding con-
ference abstracts, we had contacted the study authors by
email and/or telephone communication.
2.4.DataAnalysis. Thestatisticalpackage(RevMan5.0)pro-
vided by the Cochrane Collaboration was used to analyze the
data. Dichotomous data was presented as Odds Ratio (OR),
with 95% conﬁdence intervals (CIs). Continuous outcomes
w e r ep r e s e n t e da sw e i g h t e dm e a nd i ﬀerence, with 95% CI.
Analyses were performed by intention-to-treat where pos-
sible. Otherwise, for dichotomous outcomes, patients with
incomplete or missing data were included in sensitivity anal-
yses by counting them alternately as treatment failures or
successes.Forcontinuousvariablesweusedsimplesensitivity
analysis to test how robust the results were under diﬀerent
assumptions about what might have happened to patients
with missing data.
and abstracts screened
2 4 5e x c l u d e df o r
uplicated d paper or conference
further evaluation
35 unclear outcome measure
eli i g ble reports
23 excluded for not a
randomised trial
34 studies included in
337 potentialy relevant citations
paper mismatch (included criterion)
92 articles for
57 potentialy
the meta-analysis
Figure 1: The Quality of Reporting of Meta-analyses ﬂow diagram
for the meta-analysis.
Meta-analysis was only performed within comparisons
whereindividualtrialswerecomparedwithsimilartreatment
and control interventions.
3. Results
3.1. Study Identiﬁcation and Characteristics. An initial search
identiﬁed 337 potentially relevant articles. A total of 245
articles were initially excluded because of duplicate publi-
cation, and then 35 articles were excluded because they did
not meet our inclusion criteria. From the identiﬁed 57 po-
tentially eligible reports, 23 articles out of 57 were excluded
for further assessment. The most frequent reasons for exclu-
sion were other types of intervention examined, either no
clinical outcomes reported, or not a randomized trial so that
a total of 34 studies (2319 participants) were included into
the review. All studies were published in Chinese. Figure 1
summarized the search results based on the quality of re-
porting of meta-analyses ﬂow diagram. The bibliographic
details of these trials are given in Table 1.
The age of patients in the included studies ranged from
37 to 85 years old. Most trials included more males (54%
to 89%) than females; only 1 trial included more females
(55%). All included trials applied standard western medicine
diagnostic criteria for CPHD, although some trials also used
TCM criteria in addition. The dose range of ligustrazine
hydrochloride injection was from 60mg to 800mg and dose
route was intravenous injection in all included studies. The
t o t a ld u r a t i o no ft r e a t m e n tv a r i e df r o m7t o1 5d a y s .
None of the trials have undergone assessment of patients’
routine living ability after treatment; some trials had mea-
surement of blood gas analysis and hemodynamic parame-
ters.
Only ligustrazine injection was studied in these included
trials. None of the trials was randomized, double-blind,
placebo controlled. All included trials were designed to com-
pare ligustrazine hydrochloride injection plus conventional
treatment with the conventional treatment alone.Evidence-Based Complementary and Alternative Medicine 3
T
a
b
l
e
1
:
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
i
n
c
l
u
d
e
d
s
t
u
d
i
e
s
.
I
n
c
l
u
d
e
d
s
t
u
d
i
e
s
M
e
t
h
o
d
s
P
a
r
t
i
c
i
p
a
n
t
s
I
n
t
e
r
v
e
n
t
i
o
n
s
O
u
t
c
o
m
e
s
D
a
t
e
o
f
s
t
u
d
y
F
i
r
s
t
a
u
t
h
o
r
D
o
u
b
l
e
-
b
l
i
n
d
S
e
t
t
i
n
g
s
n
A
g
e
(
y
e
a
r
s
)
G
e
n
d
e
r
E
x
p
e
r
i
m
e
n
t
g
r
o
u
p
C
o
n
t
r
o
l
g
r
o
u
p
D
e
a
t
h
C
l
i
n
i
c
a
l
s
t
a
t
u
s
Q
u
a
l
i
t
y
o
f
l
i
f
e
H
e
m
o
r
h
e
o
l
o
g
y
A
d
v
e
r
s
e
e
ﬀ
e
c
t
1
9
9
9
C
h
e
n
Y
e
s
H
7
2
/
5
2
4
5
–
8
5
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
2
0
0
–
2
4
0
m
g
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
K
2
0
1
0
C
h
e
n
N
o
H
4
6
/
4
6
6
1
–
7
7
6
9
±
5
.
6
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
1
0
0
m
g
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
K
2
0
1
0
Y
u
a
n
N
o
H
3
1
/
3
1
N
K
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
L
i
g
u
s
t
r
a
z
i
n
e
H
y
d
r
o
c
h
l
o
r
i
d
e
i
n
j
e
c
t
i
o
n
4
0
m
L
,
6
0
m
L
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
o
Y
e
s
N
o
Y
e
s
N
K
2
0
0
9
B
a
i
N
o
H
3
5
/
3
5
5
8
–
8
0
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
8
0
m
g
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
o
Y
e
s
N
o
Y
e
s
N
o
2
0
0
9
A
n
N
o
H
4
0
/
3
8
5
9
–
8
1
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
1
2
0
m
g
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
K
2
0
0
9
H
a
o
N
o
H
5
0
/
5
0
5
5
–
7
5
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
4
0
0
m
g
q
d
.
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
K
2
0
0
9
W
u
N
o
H
3
0
/
3
0
6
2
±
1
0
.
5
/
6
0
±
1
1
.
5
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
4
0
0
m
g
q
d
.
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
K
2
0
0
9
W
u
N
o
H
4
0
/
4
0
5
0
–
7
0
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
8
0
0
m
g
q
d
.
7
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
N
o
N
o
N
o
N
K
2
0
0
9
M
a
N
o
H
3
6
/
3
6
4
8
–
8
2
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
4
0
0
m
g
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
K
2
0
0
8
L
i
N
o
H
3
1
/
3
0
5
1
±
6
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
1
0
0
m
g
q
d
.
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
K
2
0
0
8
L
i
u
N
o
H
3
8
/
3
6
M
e
a
n
6
5
.
2
/
6
5
.
6
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
1
2
0
–
2
4
0
m
g
q
d
.
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
Y
e
s
N
K
2
0
0
8
Q
i
N
o
H
3
4
/
3
0
5
7
–
8
2
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
1
0
0
m
L
.
q
d
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
o
Y
e
s
N
o
Y
e
s
N
K
2
0
0
8
Y
e
N
o
H
3
2
/
3
2
6
5
±
8
.
2
/
6
4
±
8
.
6
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
1
2
0
m
g
.
q
d
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
o
Y
e
s
N
o
N
o
N
o
2
0
0
8
X
i
e
N
o
H
5
6
/
4
9
3
6
–
7
5
M
e
a
n
6
6
.
5
/
3
8
–
7
7
M
e
a
n
6
7
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
8
0
m
g
.
q
d
o
r
b
i
d
.
1
0
–
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
Y
e
s
N
K
2
0
0
7
F
a
n
N
o
H
2
2
/
2
1
7
2
±
9
.
7
/
7
0
.
5
±
8
.
5
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
L
i
g
u
s
t
r
a
z
i
n
e
H
y
d
r
o
c
h
l
o
r
i
d
e
i
n
j
e
c
t
i
o
n
1
0
0
m
L
.
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
o
Y
e
s
N
o
Y
e
s
Y
e
s
2
0
0
7
S
u
n
N
o
H
4
0
/
4
0
6
3
.
6
7
±
1
4
.
1
5
/
6
7
.
2
5
±
1
0
.
6
4
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
L
i
g
u
s
t
r
a
z
i
n
e
H
y
d
r
o
c
h
l
o
r
i
d
e
i
n
j
e
c
t
i
o
n
1
6
0
m
g
.
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
Y
e
s
N
K4 Evidence-Based Complementary and Alternative Medicine
T
a
b
l
e
1
:
C
o
n
t
i
n
u
e
d
.
I
n
c
l
u
d
e
d
s
t
u
d
i
e
s
M
e
t
h
o
d
s
P
a
r
t
i
c
i
p
a
n
t
s
I
n
t
e
r
v
e
n
t
i
o
n
s
O
u
t
c
o
m
e
s
D
a
t
e
o
f
s
t
u
d
y
F
i
r
s
t
a
u
t
h
o
r
D
o
u
b
l
e
-
b
l
i
n
d
S
e
t
t
i
n
g
s
n
A
g
e
(
y
e
a
r
s
)
G
e
n
d
e
r
E
x
p
e
r
i
m
e
n
t
g
r
o
u
p
C
o
n
t
r
o
l
g
r
o
u
p
D
e
a
t
h
C
l
i
n
i
c
a
l
s
t
a
t
u
s
Q
u
a
l
i
t
y
o
f
l
i
f
e
H
e
m
o
r
h
e
o
l
o
g
y
A
d
v
e
r
s
e
e
ﬀ
e
c
t
2
0
0
6
S
h
u
i
N
o
H
3
1
/
2
8
6
7
±
1
2
/
6
6
±
1
1
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
4
0
0
m
g
.
q
d
.
7
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
Y
e
s
N
K
2
0
0
6
W
e
i
N
o
H
2
9
/
2
2
5
9
–
8
1
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
8
0
m
g
.
q
d
.
7
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
K
2
0
0
6
Z
h
u
N
o
O
u
t
p
a
t
i
e
n
t
1
2
/
1
2
4
7
–
8
5
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
8
0
m
g
.
q
d
.
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
o
2
0
0
6
W
a
n
g
N
o
H
1
2
0
/
8
0
4
0
–
8
5
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
1
0
0
m
g
.
q
d
.
1
0
–
1
5
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
Y
e
s
N
K
2
0
0
6
X
u
N
o
H
3
6
/
3
4
5
6
–
8
2
,
6
5
.
4
±
6
.
3
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
1
6
0
m
g
.
q
d
.
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
K
2
0
0
5
H
u
a
n
g
N
o
H
3
0
/
3
0
4
9
–
7
1
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
8
0
m
g
.
q
d
.
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
k
Y
e
s
N
o
N
o
N
k
2
0
0
5
L
i
u
N
o
H
3
0
/
3
0
5
9
–
7
5
,
6
4
.
2
±
1
0
.
5
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
4
0
0
m
g
.
q
d
.
1
0
–
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
Y
e
s
N
o
2
0
0
5
P
a
n
N
o
H
1
6
/
1
6
6
0
–
8
9
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
1
6
0
m
g
.
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
Y
e
s
N
K
2
0
0
4
G
a
o
N
o
H
2
3
/
2
0
5
5
–
8
0
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
8
0
m
g
.
q
d
.
1
5
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
Y
e
s
Y
e
s
N
o
N
o
N
o
2
0
0
4
M
a
N
o
H
3
0
/
3
0
5
0
–
7
0
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
8
0
0
m
g
.
q
d
.
7
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
o
Y
e
s
N
o
N
o
N
K
2
0
0
4
Z
h
a
n
g
N
o
H
3
0
/
2
5
5
3
–
7
9
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
2
0
0
m
g
.
q
d
.
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
o
Y
e
s
N
o
N
o
N
K
2
0
0
3
L
i
u
N
o
H
2
6
/
2
6
5
6
–
8
2
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
2
0
0
m
g
.
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
o
Y
e
s
N
o
Y
e
s
N
O
2
0
0
1
X
i
a
N
o
H
4
7
/
4
1
5
8
–
7
3
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
2
0
0
–
2
4
0
m
g
.
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
o
2
0
0
1
Z
h
u
N
o
H
3
0
/
3
0
s
t
r
a
t
i
ﬁ
e
d
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
8
0
0
m
g
.
q
d
.
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
Y
e
s
Y
e
s
N
o
Y
e
s
N
o
2
0
0
0
S
u
n
N
o
H
3
6
/
3
6
N
K
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
4
0
0
m
g
.
q
d
.
1
4
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
o
Y
e
s
N
o
N
o
N
K
1
9
9
4
W
a
n
g
N
o
H
2
6
/
2
6
3
7
–
7
7
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
1
6
0
m
g
.
q
d
.
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
N
o
N
o
N
o
N
o
2
0
0
8
Z
h
o
u
N
o
H
4
9
/
4
7
N
K
M
,
F
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
p
l
u
s
l
i
g
u
s
t
r
a
z
i
n
e
i
n
j
e
c
t
i
o
n
8
0
m
g
.
q
d
.
1
0
d
a
y
s
C
o
n
v
e
n
t
i
o
n
a
l
m
e
d
i
c
i
n
e
t
r
e
a
t
m
e
n
t
N
K
Y
e
s
N
o
N
o
N
o
H
:
h
o
s
p
i
t
a
l
;
M
:
m
a
l
e
;
F
:
f
e
m
a
l
e
;
N
K
:
n
o
t
k
n
o
w
n
.Evidence-Based Complementary and Alternative Medicine 5
3.1.1. Study of Quality. The methodological quality of most
included trials was generally “poor.” No trials reported using
randomization method, yet only 1 trial mentioned double-
blind[3];noneofthetrialswasproperlyrandomized,double
blinded, placebo controlled. None of the trials had grade
a level of adequate concealment of randomization. The
remaining 33 possible RCTs did not describe the way of
randomization. None of the trials blinded the assessment
of outcome. None of the trials reported the number of pa-
tients that were lost to followup and whether they had used
intention-to-treat analysis.
3.2. Publication Bias. Although we conducted comprehen-
sive searches and tried to avoid bias, since all trials were pub-
lished in Chinese, we could not exclude potential publication
bias.
3.3. Primary Outcomes
3.3.1. New York Heart Association Classiﬁcation of Clinical
Status (NYHA Class Improved <1 Class). 32 trials (2319
patients) concluded an improvement in heart failure [3–
34]. The entire heart function classiﬁcation system used the
NYHA functional classiﬁcation method. A meta-analysis of
data on change of NYHA functional classiﬁcation showed
that ligustrazine injection plus conventional treatment had
more beneﬁt compared with conventional treatment alone.
The summary odds ratio (OR) of NYHA class improved <I
class, or worsening of heart failure was 0.22 (OR, 0.22; 95%
CI, 0.17 to 0.28) (Figure 2).
Adverse Events.
The duration of treatment in all included studies was short (7
to 15 Days). Outcomes were measured at the End of treatment.
No obvious adverse events occurred in 21 trials, and no
a d v e r s ee v e n t sw e r er e p o r t e di n1 1t r i a l s .O n et r i a lr e p o r t e d
adverse events [17], and the adverse events were described as
dry mouth and mild drowsiness, but they were not severe. It
willrecoverwithoutspecialtreatment.Therewerenoadverse
events in control group. Although we did not ﬁnd any
related information about adverse eﬀects recorded, potential
or long-time adverse eﬀects in the included trials could not
be excluded.
3.4. Secondary Outcomes.
3.4.1. Death. Deaths were reported in only 3 trials [27, 32,
35]. The total duration of treatment varied from 10 to 15
days. No death cases reported in the remaining trials. There
was no statistically signiﬁcant diﬀerence between 2 groups
(OR, 0.74; 95% CI, 0.19 to 2.81) (Figure 3).
3.4.2. Hemodynamics. Two trials provided data for Doppler
echocardiography hemodynamic change [11, 22]. At the end
of treatment, one trial showed increased ejection fraction
(weighted mean diﬀerence (WMD) 0.09, 95% CI 0.07 to
0.11) [11, 22] of ligustrazine injection plus conventional
medicine treatment group. One trial showed a signiﬁcant
increase in cardiac output (mean of the experimental group
and control group was 4.46L/min to 3.07L/min), increased
ejection fraction (mean of the experimental group and
control group was 71% to 56.9%) and increased stroke
volume (mean of the experimental group and control group
is 56.8mL to 36.8mL) [11], and there was signiﬁcant dif-
ference between the two groups, but unfortunately the trial
did not provide proper statistic analysis (no standard de-
viation).
Three trials showed a signiﬁcant decrease mean pul-
monary arterial pressure (WMD −4.77, 95% CI −5.85 to
−3.68) [11, 19, 36] (Figure 4).
3.4.3. Quality of Life. No trial assessed quality of life.
4. Discussion
Inmanyyears,westernmedicinehasmadegreatprogressand
had become the dominating and leading medical treatment
research and development worldwide. However, it has been
increasingly recognized that western medicine may some-
times fail to treat any illness, whereas such illness is report-
edly improved by the so-called complementary and alterna-
tive medicine based on a diﬀerent theory. Few relevant ar-
ticles on TCM for CPHD have been published in the English
medical journals, and the limited evaluation of TCM beyond
China reduces its external validity.
This review of randomized trials shows the current evi-
dence in ligustrazine injection for CPHD. Treatment was
applied according to a diagnosis of CPHD without further
syndrome diﬀerentiation according to traditional Chinese
methodology.Studysizesweregenerallyinsuﬃcient.Allcon-
clusions,therefore,wereimpropriate.Therewerenodescrip-
tionsofallocationconcealmentandnoassurancesthatblind-
ing was maintained. The type of conventional medicine used
and the dosages were often impropriate reported, so it was
not certain that all studies used similar medications.
Ligustrazine injection plus conventional medicine treat-
ment showed signiﬁcantly less outcomes of decreased heart
function as with “no change or worse” in comparison with
the treatment of conventional medicine alone. With mea-
surement using NYHA of clinical status (OR, 0.22; 95%
CI, 0.17 to 0.28), the treatment group had, on average, 22
percent less than those treated with conventional medicine
alone. These results were positively encouraging and promis-
ing of combining ligustrazine injection with conventional
treatment, which might be beneﬁcial to heart function. The
positive ﬁndings were also observed in mean pulmonary
arterial pressure outcome (WMD −4.77, 95% CI −5.85 to
−3.68). In our opinion, such an average diﬀerence would
be noticeable and clinically meaningful. In addition, patients
treatedwithligustrazineinjectionmayhaveabeneﬁcialeﬀect
on cardiac output, ejection fraction, and stroke volume,
however, there is just one study providing this result. As for
other outcomes, such as death, there were just 3 trials (total
n = 215), which showed no signiﬁcant diﬀerence in favour6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Comparison of ligustrazine hydrochloride injection + conventional treatment versus conventional treatment. Lack of
improvement in heart failure (NYHA class improved <I class or worsening of heart failure). M-H: Mantel-Haenszel formula.
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Figure 3: Comparison of death rate in ligustrazine hydrochloride injection + conventional treatment versus conventional treatment.
of the ligustrazine injection plus conventional combination
treatment (OR, 0.74; 95% CI, 0.19 to 2.81).
Adverse eﬀects were reported by Shaodong and Xuefen
(2007) [17] as only dry mouth and mild drowsiness, and the
adverse events were not severe. They spontaneously recov-
ered without special treatment. No obvious adverse events
occurred in 21 trials. 11 trials did not report adverse ef-
fects and these were not signiﬁcantly diﬀerent between the
two treatments. However, the concrete conclusion regarding
safety cannot be determined from this review due to the lim-
ited evidence provided by the eligible trials. In order to prop-
er assess the safety of ligustrazine injection, large-scale clin-
ical trials with long-term followup are required.
The application of traditional Chinese herbal medicine
is fundamentally prescribed with syndrome diﬀerentia-
tion. Failure to apply syndrome diﬀerentiation may result inEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Comparison of mean pulmonary arterial pressure in ligustrazine hydrochloride injection + conventional treatment versus
conventional treatment. SD: standard deviation.
treatments being ineﬀective or even harmful. Despite this,
there is some evidence that these Chinese herbal medicines,
combined with conventional medicine and given in a way
thatisnotinkeepingwiththeirnormalusewithintraditional
Chinese medicine, may be beneﬁcial for people with CPHD
across a range of outcomes. If these medicines are used prop-
erly the positive eﬀects could be enhanced.
The improvement of heart failure was noticed in the sur-
vey; however, the eﬀects may not be true due to improper
study design or method used, such as lack of randomization
or allocation concealment. Publication bias could also be a
factor. we tried to take all measures to contact authors to get
further information either by telephone, letter, or email. Un-
fortunately, we got no replies, and we are not sure, the trials
were conducted as true RCT. Subsequently, no clear conclu-
sion could be made from these trials.
5. Conclusions
In conclusion, because of the unclear methodological quality
of these identiﬁed trials, a deﬁnite conclusion on eﬃcacy and
adverse events associated with ligustrazine injection cannot
be drawn from this review. We found no evidence of a ben-
eﬁcial eﬀect on the primary measure of eﬃcacy to support
the routine use of ligustrazine injection for CPHD. However
the drug appeared to have no major adverse eﬀects, and if
its positive eﬀects were conﬁrmed by comprehensive clinical
trials, it would lead to many promising treatments for CPHD
and could beneﬁt all patients all over the world. Therefore,
further thorough investigation, large-scale, proper study
design, randomized trials of ligustrazine injection for CPHD
will be required to justify the eﬀects reported here. Future
trials should overcome the limitations of the trials presented
in this review; particularly, they should assure adequate con-
cealmentofallocationandblindingofoutcomeassessorsand
use functional outcome as the primary outcome measured at
long-term followup. Reports of the trials should conform to
therecommendationsoftheCONSORTstatement.Ifreliable
RCT results conﬁrmed ligustrazine injection’s positive eﬀects
for treatment of CPHD, it would be blessing news for CPHD
patients worldwide.
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